An observational study in Heart Failure, sponsored by Bristol-Myers Squibb. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-20.
Sponsored by Bristol-Myers Squibb · Observational
A study of participants hospitalized with acute heart failure with reduced ejection fraction
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 99,209 is above the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will be patients who were hospitalized with acute heart failure with an average reduced ejection fraction≤40during hospitalization, and who do not have a coincident myocardial infarction and who have at least 6 months of activity in the database prior to the hospitalization.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Incidence of 30 day mortality
Time frame: 30 days
Incidence of 30 day readmission
Time frame: 30 days
Incidence of a prolonged length of stay
Time frame: 30 days
Incidence of participants hospitalized with AHF with reduced ejection fraction
Time frame: 6 years
Distribution of socio-demographic characteristics in participants hospitalized for acute HFrEF
Socio-demographic characteristics will be summarized using descriptive statistics
Time frame: 6 years
Distribution of clinical characteristics in participants hospitalized for acute HFrEF
Clinical characteristics will be summarized using descriptive statistics
Time frame: 6 years
This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb